LOGIN  |  REGISTER
Astria Therapeutics

BeiGene (NASDAQ: BGNE) Stock Quote

Last Trade: US$156.39 1.31 0.84
Volume: 101,621
5-Day Change: -7.80%
YTD Change: -13.29%
Market Cap: US$16.330B

Latest News From BeiGene

Results from the global, Phase 3 RATIONALE 302 trial showed TEVIMBRA prolonged the survival of patients who received prior systemic treatment compared to chemotherapy Approval represents the first indication in the U.S. for TEVIMBRA BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 14, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S.... Read More
Armenia and Nepal are the first of 29 countries to receive BRUKINSA SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 13, 2024 / Business Wire / The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene , a global oncology company, and the BeiGene Foundation, a nonprofit... Read More
BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approval based on positive results from ROSEWOOD trial showing BRUKINSA plus obinutuzumab achieved higher overall response rate versus obinutuzumab alone BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 07, 2024 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE:... Read More
Multiple trials underscore the potential of tislelizumab-containing immuno-oncology combinations in a variety of solid tumor settings Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 06, 2024 / Business Wire / BeiGene,... Read More
Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 29, 2024 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC) of the... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 28, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5 th , 2024 at 9:50 am ET; and Leerink Partners Global Biopharma Conference on Monday, March 11... Read More
Application based on results from global Phase 3 RATIONALE-305 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival in advanced gastric/GEJ cancer Prescription Drug User Fee Act target action date set for December 2024 BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 27, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today... Read More
Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods Strengthened leadership in hematology with global BRUKINSA ® (zanubrutinib) sales of $413 million and $1.3 billion for the quarter and full year, increases of 135% and 129% Progressed innovative hematology pipeline with initiation of four... Read More
Recommendation based on results of three Phase 3 clinical trials demonstrating benefit of tislelizumab as a first- and second-line treatment for patients with NSCLC BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 26, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European... Read More
BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in Canada Follicular lymphoma (FL) is the 2nd most common type of non-Hodgkin lymphoma (NHL) This is the fifth Canadian therapeutic indication for BRUKINSA TORONTO , Feb. 7, 2024 /CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for the use of... Read More
BRUKINSA is now listed on the RAMQ and ODB formularies. Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings. Approximately 2,000 Canadians are diagnosed every year with CLL, the most common form of leukemia in adults. TORONTO , Jan. 31, 2024 /CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jan 23, 2024 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors. Dr. Brandicourt will join the audit committee of the Board. Dr. Brandicourt replaces Thomas Malley, who has served on the Board since 2016. “Dr. Brandicourt brings a... Read More
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of BRUKINSA versus IMBRUVICA ® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the only Phase 3 Bruton’s tyrosine kinase (BTK) inhibitor trial to demonstrate superiority versus IMBRUVICA BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Dec 22, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160;... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Dec 21, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 th , 2024 with a presentation at 1:30 pm PT. A live webcast of this event can be accessed from the investors section of BeiGene’s... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Nov 29, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad... Read More
BRUKINSA ® (zanubrutinib) continues to show progression free survival (PFS) benefit compared with ibrutinib in extended follow-up of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) in the ALPINE trial Results of several studies reinforce the favorable efficacy and safety profile for BRUKINSA, including in patients switching from other Bruton’s tyrosine kinase... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & WALTHAM, Mass. / Nov 21, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and Ensem Therapeutics, Inc. (ENSEM), a biotechnology company focusing on high-value and difficult-to-drug oncology targets, today announced an agreement for BeiGene to acquire an exclusive global license to an Investigational New Drug (IND)... Read More
BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in the European Union Approval was based on results from the ROSEWOOD trial in which BRUKINSA plus the anti-CD20 monoclonal antibody obinutuzumab achieved higher overall response rate compared to obinutuzumab alone BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Nov 17, 2023 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE:... Read More
Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage Global sales of BRUKINSA totaled $358 million, a 130% increase from the prior-year period, driven by launches in the U.S. and Europe First TEVIMBRA approval in EU for 2L esophageal squamous cell carcinoma (ESCC) accelerates global... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Nov 08, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Jefferies London Healthcare Conference on Wednesday, November 15 th , 2023 with a fireside chat at 2:00 pm GMT. A live webcast of this event can be accessed from the investors section of BeiGene’s... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 20, 2023 / Business Wire / BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a final draft guidance (FDG) recommending BRUKINSA ® (zanubrutinib) for the treatment of eligible adult patients with: Untreated chronic... Read More
First-line tislelizumab plus chemotherapy demonstrated a median overall survival of 15.0 months versus 12.9 months for placebo plus chemotherapy in the intent-to-treat group of the Phase 3 RATIONALE 305 trial The safety profile for tislelizumab in combination with chemotherapy was manageable and in line with the known safety profile of anti-PD-1 antibodies BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 17, 2023 /... Read More
Late-breaking ESMO data show 56.2% of patients with resectable NSCLC who received tislelizumab plus chemotherapy before surgery achieved major pathological response, versus 15.0% of those treated with neoadjuvant chemotherapy alone Analysis also found 40.7% of patients on the tislelizumab-based regimen achieved the key secondary endpoint of pathological complete response, compared to 5.7% of patients who received neoadjuvant... Read More
Two late-breaking abstracts highlight tislelizumab plus chemotherapy combination strategy in solid tumors with high unmet need Additional presentations showcase potential of biology-driven tislelizumab combination approaches with BeiGene pipeline molecules BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 16, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,... Read More
CHMP recommends approval for BRUKINSA plus obinutuzumab as a treatment for adult patients who have received at least two prior lines of therapy If approved, BRUKINSA will be the first and only BTK inhibitor approved for follicular lymphoma BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Oct 13, 2023 / Business Wire / BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the... Read More
European Commission approves TEVIMBRA for previously treated advanced or metastatic esophageal squamous cell carcinoma (ESCC) U.S. FDA accepts Biologics License Application in first-line advanced ESCC BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Sep 19, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the European Commission (EC) has... Read More
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio, potentially pairing with more than 20 internal investigational assets as part of a broad, flexible combination strategy Regaining global rights furthers Company’s mission of bringing innovative, affordable medicines to more patients and... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Aug 31, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11 th , 2023 with a fireside chat at 9:20 am ET. A live webcast of this event can be accessed from the investors section of... Read More
HealthStocksHub
Recorded total product revenue of $554 million in the quarter, an increase of 82% from the prior-year period, driven by increased sales of BRUKINSA ® worldwide Global sales of BRUKINSA totaled $308 million in the quarter, a 139% increase from the prior-year period and a 46% increase from the prior quarter; continued execution... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jul 21, 2023 / Business Wire / BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval for tislelizumab as monotherapy for the treatment of adult patients with unresectable, locally... Read More
Submission seeks approval for BRUKINSA in combination with obinutuzumab as a treatment for relapsed or refractory follicular lymphoma BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jul 12, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application... Read More
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SUZHOU, China & SHANGHAI / Jul 10, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and DualityBio, a next-generation ADC... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass / Jul 07, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor Research and Development Day in New York City and via webcast on July 18, 2023. John V. Oyler, BeiGene's Co-Founder, Chairman and CEO, along with the Company's leadership team, will provide an update on... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is aware that Pharmacyclics LLC has filed a complaint against BeiGene, Ltd. and BeiGene USA, Inc., alleging that BeiGene’s BRUKINSA® infringes a Pharmacyclics patent issued on June 13, 2023. BeiGene’s work is original, and we will vigorously defend against all... Read More
Oral presentation for the ROSEWOOD trial of BRUKINSA in relapsed or refractory follicular lymphoma Additional presentations expand existing evidence base for BRUKINSA across B-cell malignancies BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will present data on its Bruton’s tyrosine... Read More
New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA ® (zanubrutinib) reinforce potential across various B-cell malignancies Early results for BTK-targeted CDAC (BGB-16673) and BCL-2 inhibitor (BGB-11417) in various B-cell malignancies illustrate promise of pipeline BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Jun 09, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:... Read More
BeiGene’s BTKi is approved in more than 65 markets globally BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 30, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia... Read More
HealthStocksHub
Two global Phase 3 trials in adults with CLL demonstrated superior efficacy for BRUKINSA in first line and relapsed/refractory settings TORONTO , May 30, 2023 /CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's tyrosine... Read More
Highlights from early- and late-stage pipeline include combination data for cornerstone therapies BRUKINSA and tislelizumab early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 25, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data showcasing the range of... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 24, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31st at 12:00 pm ET; and Goldman Sachs 44th Annual Global Healthcare Conference on Monday,... Read More
SEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 17, 2023 / Business Wire / The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation , a nonprofit charitable foundation, today announced a collaboration to provide access... Read More
BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / May 06, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA... Read More
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA ® in the U.S. for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); global BRUKINSA product revenue totaled $211.4 million, more than doubling from first quarter 2022 Continued to build on leading position in China oncology market, supported by... Read More
HealthStocksHub
Early-stage data for differentiated anti-OX40 agnostic antibody BGB-A445 and BCL-2 inhibitor BGB-11417 complement the growing body of data supporting cornerstone assets zanubrutinib and tislelizumab BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 26, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:... Read More
Newly Released Report Details Company’s Progress and Plans for Growing Responsibly BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 25, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the... Read More
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 20, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn. / Apr 17, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced or... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn. / Apr 17, 2023 / Business Wire / MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients with advanced or... Read More
PD-1 inhibitor tislelizumab under review by Brazil’s National Health Surveillance Agency to treat non-small cell lung cancer and esophageal cancer Future regional expansion planned in Argentina, Mexico, Chile, Colombia, Uruguay, and other countries BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Apr 13, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced... Read More
Pryor will spearhead BeiGene’s efforts to pair global health equity with diversity and inclusion BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 30, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the appointment of Julius Pryor III as its first Global Head of Diversity and Health Equity, effective immediately. Mr. Pryor has more than 30 years of... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Mar 21, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S. presence. The company announced today that the last piece of structural steel will be laid at its Hopewell, NJ campus today. This new facility will provide state-of-the-art commercial-stage U.S. biologic... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 27, 2023 / Business Wire / BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones. “We had an outstanding fourth quarter and 2022, with revenues from our two cornerstone medicines, BRUKINSA ® and tislelizumab,... Read More
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING / Feb 24, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in Cowen’s 43 rd Annual Healthcare Conference on Monday, March 6 th , 2023 with a fireside chat at 11:10 am ET. Live webcasts of these events can be accessed from the investors section of BeiGene’s website at... Read More
First and only BTK inhibitor to be granted provincial formulary approval TORONTO , Feb. 6, 2023 /CNW/ - BeiGene Canada, the affiliate of BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that the Government of Quebec will publicly fund BRUKINSA ® (zanubrutinib), a second generation inhibitor of Bruton's tyrosine kinase (BTK), for the treatment of adult patients with... Read More
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. / Feb 03, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, has released a report highlighting the challenges cancer patients and caregivers face in managing mental and emotional well-being. The data summarized in the report is based on a BeiGene-sponsored study by Cancer Support Community (CSC), a global nonprofit... Read More
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING / Feb 01, 2023 / Business Wire / BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two upcoming investor conferences: The Guggenheim Oncology Conference 2023 on Wednesday, February 8, 2023 at 9:35 a.m. ET; and The SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at... Read More
HealthStocksHub
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate superior PFS vs IMBRUVICA ® (ibrutinib) BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,... Read More
MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorizations for BRUKINSA (zanubrutinib) in Great Britain for both the treatment... Read More
Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS ® included for the first time XGEVA ® successfully renewed BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include four new... Read More
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium,... Read More
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company today announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. PT. A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com . An archived replay will be available for 90 days following the event. About BeiGene BeiGene is... Read More
Submission seeks marketing authorization for first-line treatment of unresectable or metastatic hepatocellular carcinoma BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental biologics license application (sBLA) for tislelizumab in patients with first-line... Read More
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING--( BUSINESS WIRE )-- BeiGene (NASDAQ: BGNE; HKEX: 06160;... Read More
SAN DIEGO , Dec. 8, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced a clinical supply agreement with BeiGene, Ltd. (NASDAQ: BGNE) to evaluate the safety and efficacy of Phanes' PT199, a differentiated anti-CD73 monoclonal antibody in combination with BeiGene's tislelizumab, an anti-PD-1 monoclonal... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB